| 30th Dec |
Update on Omni Innovation Investment |
| 28th Dec |
RGP: Refresh Invests in Technology Company |
| 23rd Dec |
Appendix 3B |
| 23rd Dec |
Prospectus |
| 23rd Dec |
Reinstatement to Official Quotation |
| 23rd Dec |
$1.6m Placement for Omni Innovation Investment |
| 22nd Dec |
Net Tangible Asset Backing |
| 14th Dec |
Withdrawal of Entitlement Issue |
| 14th Dec |
Suspension from Official Quotation |
| 12th Dec |
Trading Halt |
| 9th Dec |
Notification of Rights Issue Shortfall |
| 2nd Dec |
Omni Innovation Market Update |
| 25th Nov |
Rights Issue Offer Document |
| 22nd Nov |
Results of Meeting |
| 22nd Nov |
Becoming a Substantial Holder |
| 21st Nov |
Omni Innovation secures UK Distribution Deal |
| 18th Nov |
Letter to Shareholders |
| 16th Nov |
Appendix 3B |
| 16th Nov |
Appendix 3B and Cleansing Notice |
| 16th Nov |
Non-Renounceable Rights Offer |
| 16th Nov |
Letter to Optionholders |
| 14th Nov |
Net Tangible Asset Backing |
| 10th Nov |
Reinstatement to Official Quotation |
| 10th Nov |
Placement to Chinese Pharmaceutical and Investment Group |
| 3rd Nov |
Voluntary Suspension |
| 1st Nov |
Trading Halt |
| 1st Nov |
Appendix 4C - Quarterly |
| 1st Nov |
Appendix 4C - Quarterly |
| 21st Oct |
Annual Report to Shareholders |
| 21st Oct |
Notice of Annual General Meeting/Proxy Form |
| 21st Oct |
Appendix 4G and Corporate Governance Statement |
| 14th Oct |
Net Tangible Asset Backing |
| 13th Oct |
EVE Investments Webcast on Omniblend Innovation |
| 30th Sep |
Extension of Omniblend Innovation Tranche 2 Settlement |
| 21st Sep |
New Study- GlucoControl Improves Long-Term Glycaemic Control |
| 14th Sep |
Update on Omniblend Innovation |
| 9th Sep |
Net Tangible Asset Backing |
| 1st Sep |
Appendix 4E and Full Year Statutory Accounts |
| 24th Aug |
Omniblend Innovation Enters into US Representation Deal |
| 12th Aug |
Net Tangible Asset Backing |
| 27th Jul |
Appendix 4C - Quarterly |
| 14th Jul |
Net Tangible Asset Backing |
| 12th Jul |
Omniblend Innovation Appoints Director of Sales & Marketing |
| 8th Jul |
GlucoControl for type 2 diabetes named Product of the Month |
| 5th Jul |
GlucoControl Momentum |
| 10th Jun |
Net Tangible Asset Backing |
| 31st May |
Appendix 3B and Change of Director's Interest Notice x 3 |
| 31st May |
Results of Meeting |
| 13th May |
Net Tangible Asset Backing |
| 12th May |
Exclusive Engagement Signed with OHC for Scandinavia |
| 6th May |
GlucoControl Pre-Meal Drink Launched |
| 3rd May |
Appendix 3B |
| 29th Apr |
Notice of General Meeting/Proxy Form |
| 26th Apr |
Appendix 4C - Quarterly |
| 22nd Apr |
Omniblend Innovation Transaction Completed |
| 15th Apr |
Net Tangible Asset Backing |
| 1st Apr |
Extension of Omniblend Innovation Tranche 2 Settlement |
| 1st Apr |
Change in Substantial Holding |
| 31st Mar |
Med-Tech Executive Joins EVE Board |
| 21st Mar |
Completion of $1.85M Non-Renounceable Rights Issue |
| 4th Mar |
Net Tangible Asset Backing |
| 1st Mar |
Half Yearly Report and Accounts |
| 25th Feb |
GlucoControl Product Manufacturing Commences |
| 22nd Feb |
Letter to Shareholders |
| 18th Feb |
Fully Underwritten Rights Issue |
| 18th Feb |
Prospectus |
| 18th Feb |
Appendix 3B |
| 18th Feb |
Letter to Optionholders |
| 15th Feb |
Net Tangible Asset Backing |
| 3rd Feb |
Investor Presentation - Omniblend Innovation Acquisition |
| 2nd Feb |
Shareholder Update |
| 29th Jan |
Appendix 4C - Quarterly |
| 13th Jan |
Net Tangible Asset Backing |
| 12th Jan |
Change in Substantial Holding |
| 4th Jan |
Change of Director's Interest Notice x 2 |
| 4th Jan |
Appendix 3B |
